- Home
- SKYE vs HYPR Comparison
SKYE vs HYPR Comparison
Compare SKYE & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- HYPR
- Stock Information
- Founded
- SKYE 2012
- HYPR 2014
- Country
- SKYE United States
- HYPR United States
- Employees
- SKYE N/A
- HYPR N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- HYPR Medical Specialities
- Sector
- SKYE Health Care
- HYPR Health Care
- Exchange
- SKYE Nasdaq
- HYPR Nasdaq
- Market Cap
- SKYE 121.8M
- HYPR 137.5M
- IPO Year
- SKYE N/A
- HYPR N/A
- Fundamental
- Price
- SKYE $1.33
- HYPR $1.33
- Analyst Decision
- SKYE Strong Buy
- HYPR Strong Buy
- Analyst Count
- SKYE 5
- HYPR 3
- Target Price
- SKYE $14.75
- HYPR $1.28
- AVG Volume (30 Days)
- SKYE 1.8M
- HYPR 964.4K
- Earning Date
- SKYE 11-06-2025
- HYPR 11-11-2025
- Dividend Yield
- SKYE N/A
- HYPR N/A
- EPS Growth
- SKYE N/A
- HYPR N/A
- EPS
- SKYE N/A
- HYPR N/A
- Revenue
- SKYE N/A
- HYPR $10,797,000.00
- Revenue This Year
- SKYE N/A
- HYPR $12.92
- Revenue Next Year
- SKYE N/A
- HYPR $32.10
- P/E Ratio
- SKYE N/A
- HYPR N/A
- Revenue Growth
- SKYE N/A
- HYPR N/A
- 52 Week Low
- SKYE $1.14
- HYPR $0.53
- 52 Week High
- SKYE $5.96
- HYPR $2.22
- Technical
- Relative Strength Index (RSI)
- SKYE 27.04
- HYPR 43.16
- Support Level
- SKYE $1.50
- HYPR $1.23
- Resistance Level
- SKYE $1.76
- HYPR $2.22
- Average True Range (ATR)
- SKYE 0.24
- HYPR 0.20
- MACD
- SKYE -0.15
- HYPR -0.06
- Stochastic Oscillator
- SKYE 0.68
- HYPR 8.59
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.